The pulmonary vasoconstrictor, thromboxane, may contribute to the development of pulmonary hypertension. Our objective was to determine if a combined thromboxane synthase inhibitor/receptor antagonist, terbogrel, prevents pulmonary hypertension and the development of aberrant pulmonary arterial responses in newborn piglets exposed to 3 days hypoxia. Piglets were maintained in room air (control) or 11% O 2 (hypoxic) for 3 days.
INTRODUCTION
Newborns with serious, unresolved lung and heart disorders sometimes develop pulmonary hypertension. Unfortunately, treatment of infants suffering from chronic types of pulmonary hypertension has advanced minimally and is largely limited to attempts to maintain good oxygenation and reverse the underlying pathology (1, 4) . Moreover, most research has been aimed at devising therapies to acutely decrease pulmonary arterial pressure once pulmonary hypertension is well established. Therapies to prevent the development and progression of pulmonary hypertension in infants with chronic cardiorespiratory disorders have received little attention.
Chronic hypoxia has long been implicated in the pathogenesis of pulmonary hypertension in infants with chronic cardio-respiratory conditions (4, 38, 39) . For example, it is has been shown by many investigators, including us, that pulmonary hypertension develops when newborn animals are exposed to chronic hypoxia (6, 8, 13, 18, 28) .
Identifying the changes in the pulmonary circulation that occur at early stages of chronic hypoxia-induced pulmonary hypertension are key to understanding the pathogenesis and to developing therapies to intervene with its progression. We have previously found that newborn piglets exposed to 3 days of chronic hypoxia develop pulmonary hypertension and exhibit diminished pulmonary arterial dilation to acetylcholine (ACh) (17, 20) . We have also provided evidence that production of the potent pulmonary vasoconstrictor, thromboxane (TXA 2 ), is elevated and partially mediates the diminished pulmonary arterial dilation in the hypertensive piglets (19, 20) . The purpose of this study was to test the hypothesis that treatment with a combined TXA 2 synthase inhibitor/receptor antagonist, Terbogrel, prevents the diminished ACh-induced dilation and the development of pulmonary hypertension in piglets exposed to 3 days chronic hypoxia.
METHODS

Animals
A total of 14 hypoxic piglets and a total of 6 control piglets were studied. We have previously found no differences in pulmonary vascular resistance or pulmonary vascular responses between piglets raised in a room-air environment and piglets raised on a farm (17). Therefore, for this study, all of the control piglets were studied on the day of arrival from the farm at 6-7 days of age. For the hypoxic piglets, newborn pigs were placed in a hypoxic normobaric chamber on the evening of the day of arrival from the farm at 3 days of age. They were maintained in the hypoxic chamber for 3 to 3 1/2 days, so that they were studied at age 6-7 days. Normobaric hypoxia was produced by delivering compressed air and N 2 to an incubator (Thermocare). Oxygen content was regulated at 10-11 % O 2 (PO 2 66-74 Torr), and CO 2 was maintained at 3-6 Torr by absorption with soda lime. The chamber was opened two times per day for cleaning and to weigh the piglets. The animals were fed ad libitum with an artificial sow milk replacer from a feeding device attached to the chamber. Some of the hypoxic piglets (n=7) received Terbogrel, 10 mg/kg po bid. The first dose of Terbogrel was given immediately prior to placing the piglet into the hypoxic chamber.
The choice of Terbogrel dosing was based on pharmokinetic studies in rats showing that 10 mg/kg po doses of Terbogrel were rapidly and well (90% absorbed) with a systemic availability of about 30%, and terminal half-life in the range of 10 hours (42).
Measurements in anesthetized animals.
On the day of study, all piglets were weighed and anesthetized with ketamine (30 mg/kg im) and pentobarbital sodium (10 mg/kg/ iv). Additional intravenous pentobarbital sodium was given as needed via an ear vein to maintain anesthesia during placement of the catheters. First, the trachea of the piglet was cannulated so that the animal could be ventilated if necessary. Then, a catheter was placed into the right femoral artery for JAP-01337-2004 R1 5 monitoring systemic blood pressure and arterial blood gases. To measure cardiac output by the thermodilution technique (model 9520 thermodilution cardiac output computer, Edwards Laboratory), a thermistor was placed into the aortic arch via the left femoral artery and a catheter that served as an injection port was placed into the left ventricle via the left carotid artery. Cardiac output was measured at end expiration as the mean of three injections of 3 ml of 0.9% saline (0G C). Next, another catheter was placed through the right external jugular vein into the pulmonary artery to monitor pulmonary arterial pressure.
To obtain pulmonary wedge pressure, the pulmonary arterial catheter was advanced into a distal pulmonary vessel. In some animals, wedge pressure was unable to be obtained, and left ventricular end diastolic pressure was then measured. We have previously found no difference between measurements of pulmonary wedge pressure and left ventricular end diastolic pressure in anesthetized piglets (17). The zero reference for the vascular catheters was the midthorax. After blood gases were measured, all animals were given heparin (1,000 IU/kg iv) and additional anesthesia (3-5 mg/kg of pentobarbital sodium iv) and then exsanguinated. The thorax was opened, the lungs were removed, and placed in cold (4G C) physiological saline solution (PSS) until use for either cannulated artery studies or for incubation for TXA 2 Cannulated artery studies.
Immediately prior to use, segments of 100-300 Km diameter pulmonary arteries were dissected from a lung lobe. The system used to study cannulated arteries has been described in detail previously (20, 35) . It consists of a water-jacketed plastic chamber in which proximal (inflow) and distal (outflow) cannulas were mounted. An arterial segment was threaded onto the proximal cannula, tied in place and filled with PSS. The distal end of the artery was then tied onto the distal cannula. The distance between the cannula tips was adjusted with a micrometer connected to the proximal cannula so that the slack was taken out of the artery. The exterior of the artery was suffused with PSS from a reservoir at 37G
C and aerated with a gas mixture containing O 2 , CO 2 , and N 2 , giving a PO 2 of approximately, 140 Torr, a PCO 2 of 38 Torr, and a pH of 7.37. The arterial lumen was filled from a syringe containing PSS, aerated with the same gas mixture as the reservoir, and connected to the cannula with polyethylene tubing.
Inflow pressure was adjusted by changing the height of the infusion syringe.
Pressure transducers were placed both on the inflow side between the syringe and the artery and at the outflow end of the system. Both inflow and outflow pressures were monitored continuously and the artery was discarded if the pressures were not equal (indicates leak in vessel). The external diameter of the artery was observed continuously with a video system containing a color camera (Hitachi VCC-151) and television monitor. Vessel diameters
were measured with a videoscaler (FORA IV).
Each artery was allowed to equilibrate for 40-60 min to establish basal tone. The arteries were equilibrated at transmural pressures similar to those in vivo (17) 15 cm H 2 O for control arteries and 25 cm H 2 O for hypoxic vessels. We have previously shown no effect from these transmural pressures on pulmonary arterial responses to Acetylcholine (ACh) (20). After equilibration and establishment of basal tone, the arteries were tested for viability by contraction to U46619 (10 -7 M). The presence of a functional endothelium was verified by assessing dilatory responses to the calcium ionophore, A23187 (20). The arteries were then washed with fresh PSS, and allowed to return to their precontracted diameter, i.e., allowed to reestablish basal tone.
In one series of studies, the diameter of arteries from control, untreated hypoxic, and terbogrel-treated hypoxic piglets were continuously monitored while cumulative doses of Acetylcholine (ACh, 10 -8 to 10 -5 M) were added to the reservoir at 10 min intervals. In another series of studies, the influence of elevated tone on ACh responses in arteries from each group of piglets was assessed. Tests for viability and a functional endothelium were done as described above, and then endothelin was added in increasing doses until the arterial diameter had decreased by 40-50%. The dose of endothelin needed to accomplish this tended to be greater (3-5 x 10 -9 M endothelin) for both groups of hypoxic piglets than for the control piglets (1 x 10 -9 M endothelin). After equilibration at the elevated tone, the dose response curves to ACh were performed. After each study, vessel viability was retested using U46619.
TXA 2 and PGI 2 determinations.
Pulmonary arteries (20-600 Km diameter) were dissected from control, untreated hypoxic, and terbogrel-treated hypoxic lungs, and then immediately placed in HEPES buffer of the following composition (in mM): 10 HEPES, 150 NaCl, 5 KCl, 2 CaCl 2 , 1
MgCl 2 , and 11 glucose, pH 7.4. After incubating the vessels in HEPES for 15 min., the media was collected and stored at -20G C until the time of assay for specific metabolites.
The vessels were weighed, then dried to constant weight at 60G C for at least 72 hours.
Synthesis of the stable metabolites of TXA 2 and PGI 2 , TXB 2 and 6-keto PGF1 respectively, were measured by enzyme immunoassay following standard methods and using kits from Cayman laboratories. Enzyme immunoassay determinations of TXB 2 and 6-keto PGF1 were normalized to vessel dry weight.
Materials. Concentrations for each drug listed in the preceding paragraphs were expressed as final molar concentrations in the vessel bath. ACh was obtained from Sigma Chemical and was solubilized in saline. A23187 was from Biomol and was solubilized in DMSO.
Endothelin, from Calbiochem and U46619, from Caymen Chemical, were solubilized in ethanol.
Statistics. Data are presented as means ± SEM. One way ANOVA with post hoc multiple comparison test was used to compare measurements between control, untreated hypoxic and terbogrel-treated hypoxic piglets. P < 0.05 was considered significant.
RESULTS
The measured values of blood pH, PO 2 and PCO 2 obtained during hemodynamic measurements in anesthetized piglets breathing room air were similar between all groups of piglets ( Table 1) . Measurements of pulmonary arterial pressure, pulmonary wedge pressure, cardiac output and aortic pressure in the anesthetized piglets are shown in Table 2 .
Pulmonary arterial pressure and pulmonary wedge pressure were greater in both untreated After equilibration at baseline tone, the mean diameter of all vessels used in the cannulated artery studies was 230±6 Km for arteries from control piglets, 250±6 Km for arteries from untreated hypoxic arteries and 260±6 Km for arteries from Terbogrel-treated hypoxic piglets. None of the vehicles significantly changed arterial diameter in the concentrations used to solubilize any of the agents.
For control arteries studied at basal tone (n=8 arteries from 5 piglets), vessel diameter increased to all but the highest dose of ACh (Fig. 2 A) . For both groups of chronic hypoxic arteries studied at basal tone, the diameter decreased to all doses of ACh and the magnitude of decrease was less for Terbogrel-treated (n=14 arteries from 7 piglets) than for untreated (n=7 arteries from 5 piglets) arteries at the two lowest doses of ACh (Fig. 2 A) .
When tone was elevated with endothelin, arteries from all groups of piglets dilated to all doses of ACh (Fig. 2 B) although the dilation to the highest dose of ACh was less for both untreated and Terbogrel-treated groups of chronic hypoxic arteries than for control arteries (n=6 arteries from 6 piglets). Notably, dilation to the highest dose of ACh was greater for arteries from Terbogrel-treated (n=7 arteries from 7 piglets) chronic hypoxic piglets than for arteries from untreated (n=7 arteries from 7 piglets) chronic hypoxic piglets (Fig. 2 B) .
Enzyme immunoassay determinations of the media from incubated arteries showed that production of 6-keto-PGF1 , the stable metabolite of PGI 2 , was less for both untreated (n=12 samples from 6 piglets) and Terbogrel-treated (n=12 samples from 4 piglets) groups of chronic hypoxic piglets than for control piglets (n=12 samples from 6 piglets) (Fig, 3 A) .
By comparison, production of TXB 2 , the stable metabolite of TXA 2 , was greater for untreated chronic hypoxic piglets (n=12 samples from 6 piglets) than for either Terbogreltreated chronic hypoxic piglets (n=12 samples from 4 piglets) or for control piglets (n=12 samples from 6 piglets) (Fig. 3 B) .
DISCUSSION
The findings of diminished dilation to ACh and elevated pulmonary vascular resistance in newborn piglets exposed to 3 days hypoxia are consistent with our previous findings (17, 20). The major new findings in this study are that treatment with a combined thromboxane synthase inhibitor/receptor antagonist, Terbogrel, given immediately before and throughout 3 days exposure to hypoxia, partially prevented these abnormalities in pulmonary vascular resistance and pulmonary vascular responsiveness.
The rationale for the use of Terbogrel to prevent pulmonary hypertension and pulmonary arterial dysfunction is based on evidence provided by us (19, 20) and other investigators (2, 3, 15, 27) . TXA 2 production has been found to be elevated in adults with pulmonary hypertension due to a variety of causes (15) , in children with congenital heart disease associated with pulmonary vascular disease(3), in infants with congenital diaphragmatic hernia and pulmonary hypertension (21), and in infants with persistent pulmonary hypertension of the newborn (27) . In regards to evidence from newborn animal models of pulmonary hypertension, a greater TXA 2 content was measured in lung homogenates of fetal lambs with pulmonary hypertension due to in utero ligation of the ductus arteriosus than in lung homogenates of age-matched controls (2). We recently found that resistance level pulmonary arteries of piglets with pulmonary hypertension resulting from 3 days exposure to chronic hypoxia produced greater amounts of TXA 2 than did resistance level pulmonary arteries of comparable age control piglets (19). We also provided evidence that TXA 2 is at least partly responsible for the abnormal pulmonary hypertensive rats (37), in aortas of rabbits exposed to high glucose (46), in the aorta of spontaneously hypertensive rats (25) , and in renal arteries from cholesterol fed rats (7).
Relevant to the pulmonary circulation, rings of intrapulmonary arteries from adult rabbits receptor antagonist inhibited the development of pulmonary hypertension in newborn rats exposed to hyperoxia (31) . Treatment with the COX inhibitor, aspirin, reduced the severity of pulmonary hypertension in chronically hypoxic adult rats (34). In this latter study, because COX inhibition diminishes production of both COX-dependent dilators as well as constrictors, it is perhaps not surprising that aspirin only partially inhibited pulmonary hypertension (34).
It merits comment that altered production of COX-dependent dilators, including PGI 2 , may be involved in the pathogenesis of pulmonary hypertension. PGI 2 production has been shown to be elevated in adult rats with chronic hypoxia induced pulmonary hypertension (9, 41). The elevation in PGI 2 may serve in a compensatory role to counteract pulmonary hypertension. However, in many cases of pulmonary hypertension (15, 40, 48),
including some animal models of pulmonary hypertension (6, 19) , the evidence suggests that PGI 2 production is reduced. In fact, in some studies reductions in COX-dependent dilators, such as PGI 2 , are found in association with elevated production of COX-dependent constrictors (15, 19) . In particular, we previously found that concomitant with increased TXA 2 production, resistance level pulmonary arterial PGI 2 production was decreased in piglets exposed to 3 days of chronic hypoxia (19). Thus, it seems that a shift in the balance of COX metabolites towards production of constrictors is involved in the pathogenesis of at least some forms of pulmonary hypertension (15) production (14, 23).
Because we limited our measurements to PGI 2 and TXA 2 production, we cannot rule out the possibility that due in part to shunting within the metabolic pathway, production of other arachidonic acid dependent-constrictors was increased. These include both COX and non-COX products, such as lipoxygenases (50), cytochrome P450 products (22, 51), and isoprostanes (32). In addition, constrictors other than metabolites of arachidonic acid pathways might be produced and explain why Terbogrel failed to completely inhibit pulmonary hypertension. For example, there is evidence that reactive oxygen species(5, 12, 29, 47), such as superoxide (10, 30, 44, 47) , are involved in aberrant vascular responses in both systemic and pulmonary hypertension. Endothelin might also contribute to the pathogenesis of pulmonary hypertension (16, 26).
Another possible reason why treatment with Terbogrel only partly prevented pulmonary hypertension could be that the dose used was not high enough. Our choice of dose was based on pharmokinetic studies in rats (42). That our dose yielded adequate tissue levels to inhibit TXA 2 synthesis is supported by our finding that resistance level pulmonary arterial production of the stable metabolite of TXA 2 was reduced below levels measured in arteries from untreated hypoxic piglets. However, it remains possible that production of Unfortunately, due to an unforeseen complication of leg pain, which confounded the primary end-point of walking distance, the study was discontinued.
Limitations of methodology must always be considered. For example, in our study different doses of endothelin were required to elevate tone to the same degree in arteries from hypoxic and control piglets. Differential effects from endothelin on signal transduction pathways might contribute to the difference in dilator responses to ACh between control and hypoxic piglets. Notably, as doses needed to elevate tone were similar for both Terbogrel-treated and untreated groups of hypoxic piglets, confounding influences due to endothelin are not likely to explain the difference in ACh responses between them.
To summarize, our findings show that treatment with a combined TXA 2 synthase inhibitor/receptor antagonist partially inhibited the development of both aberrant pulmonary vascular responses and elevations in pulmonary vascular resistance in piglets exposed to 3 days of chronic hypoxia. These findings provide information important to devising other potentially more effective treatment strategies to inhibit the onset and progression of chronic hypoxia-induced pulmonary hypertension in newborns. For instance, combined use of a dilator, such as PGI 2 , along with a TXA 2 synthase inhibitor/receptor antagonist might be more effective than either alone. In addition, it merits future consideration that targeting the TXA 2 pathway might be useful in acutely lowering pulmonary vascular resistance in infants with established pulmonary hypertension, particularly those infants suffering from conditions associated with chronic hypoxia. 
